HerediGENE is a test that fully analyzes a panel of genes, including BRCA1 and BRCA2, which are associated with increased risk of developing breast, ovarian and other hereditary cancers.
Comming Soon...
Mo.Re. (Molecular Response) is a multi-gene assay developed to provide an insight to the tumor’s biology of each patient.
Personalized pharmacotherapy based on human DNA.
Coming Soon...
Coming Soon...
Tumor Mutational Burden (TMB) is an emerging, independent predictive biomarker of immunotherapies in multiple tumor types, including lung cancer.
Microsatellite Instability (MSI) is a condition that appears on the DNA of specific cells (such as cancer cells) where the number of microsatellites (short repeats of DNA sequences) in these cells, is different from the repeats that existed in the DNA when it was inherited.
The PD-L1 test helps doctors determine whether a patient is likely to benefit from cancer drugs known as immune checkpoint inhibitors.
PCA3 is a non-invasive test for the detection of prostate cancer, highly specific and more precise than all other available screening tests for prostate cancer and is performed on a simple urine sample.
In Genekor, we offer Single Gene analysis with the highest quality, using the most advanced technology available.
Genekor is a Molecular Biology Laboratory, focused in Oncology. Our journey began in 2007 and we constantly grow in order to provide the highest quality services in the Molecular Oncology sector. A passionate team sharing the same vision on quality healthcare and molecular oncology is working together in order to provide patients and physicians with actionable information.
Genekor’s highly experienced scientific and management team are cooperating passionately in order to provide the physicians and patients with the highest quality services in oncology. This is us.
See Genekor' s publications and posters.
The FDA has approved the use of TMB (Tumor Mutation Burden) detection as a biomarker for the selection of pembrolizumab (Keytruda™) as a treatment for adults and pediatric patients with incurable or metastatic solid tumors.
The FDA has approved the use of TMB (Tumor Mutation Burden) detection as a biomarker for the selection of pembrolizumab (Keytruda™) as a treatment for adults and pediatric patients with incurable or metastatic solid tumors.
The approval was based in part on phase 2 Trial KEYNOTE-158, which revealed an association between high TMB and ORR response with the PD-1 inhibitor in patients with various solid tumors.
TMB refers to the total number of mutations present in the tumor genome.
Tumors with a high mutation load (TMB-H) may have a higher percentage of neo-antigens and, consequently, are expected to be more immunogenically active than tumors with a comparatively lower mutation load.
Click here to see the FDA post
18.06.2020This site uses cookies to make a perfect user experience.
